-
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
NYSE: $MRK RAHWAY, N.J.–(BUSINESS WIRE) October 26, 2026 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab… Source: Read More
-
Merck Announces Promising One-Year Results for Remigromig in Phase 2b/3 Brunello Study
NYSE: $MRK A New Frontier in Autoimmune Research Merck has officially shared positive one-year results from its pivotal Phase 2b/3 Brunello clinical trial. The study is evaluating the safety and efficacy of remigromig, an investigational anti-PD-1 therapy, specifically targeting patients living with moderate-to-severe systemic lupus erythematosus (SLE). Understanding the Brunello Study The Brunello trial is…
-
FDA Approves Label Update for Winrevair (sotatercept-csrk) Following HYPERION Trial Data
NYSE: $MRK A Significant Update for Pulmonary Arterial Hypertension Treatment The U.S. Food and Drug Administration (FDA) has officially approved a label update for Winrevair (sotatercept-csrk), marking a meaningful step forward in the treatment of pulmonary arterial hypertension (PAH). This update incorporates clinical data from the Phase 3 HYPERION trial, providing healthcare providers and patients…
-
New Hope for Kidney Cancer: FDA Approves Welireg and Lenvima Combination
NYSE: $MRK A Breakthrough in Renal Cell Carcinoma Treatment The U.S. Food and Drug Administration (FDA) has officially approved a significant new treatment option for patients battling advanced kidney cancer. The combination of Welireg (belzutifan) and Lenvima (lenvatinib) is now indicated for adult patients with advanced renal cell carcinoma (RCC) who have previously received treatment…
-
A New Frontier in Cancer Research: Understanding Merck’s Remigromig
NYSE: $MRK Targeting the Wnt Pathway In a significant move for oncology research, Merck has initiated a Phase 1 clinical trial to evaluate its investigational agent, remigromig. This novel therapy represents a sophisticated approach to cancer treatment, specifically designed as a tri-specific agonist of the Wingless-related integration site (Wnt) pathway. What is Remigromig? Remigromig is…
-
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
NYSE: $MRK Tokyo – (September 25, 2026) – The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada… Source: Read More
-
A Breakthrough in Oncology: Merck and Moderna Report Positive Phase 3 Results for Personalized Cancer Vaccine
NYSE: $MRK A Major Milestone in Cancer Treatment The landscape of cancer therapy is evolving rapidly, and a recent announcement from Merck and Moderna marks a significant turning point. The companies have officially announced that the Phase 3 INTERPATH-001 trial, investigating their investigational individualized neoantigen therapy (INT), known as mRNA-4157 (telixavastat/intismeran), combined with the immunotherapy…